More recently, Goswami et al. revealed ARID1A mutation in tumor cells and expression of immune cytokine CXCL13 in the baseline tumor tissues as two predictors of clinical response to ICB in metastatic urothelial carcinoma [70]. This evidence concerns the gene ARID1A and neoplasm.